Key Points
XLF-deficient mice recapitulate the lymphocytopenia of XLF-deficient patients.
Premature aging of hematopoietic stem cells underlies the severe and progressive lymphocytopenia in XLF-deficient mice.
Abstract
XRCC4-like factor (XLF/Cernunnos) is a component of the nonhomologous end-joining (NHEJ) pathway of double-strand DNA break repair. XLF-deficient patients develop a severe progressive lymphocytopenia. Although NHEJ is required for V(D)J recombination and lymphocyte development, XLF-deficient mice have normal V(D)J recombination, highlighting the need for an alternative mechanism for the lymphocytopenia. Here, we report that XLF-deficient mice recapitulate the age-dependent lymphocytopenia of patients. We show that XLF deficiency leads to premature aging of hematopoietic stem cells (HSCs), measured by decreased functional capacity in transplantation assays, preferential myeloid reconstitution, and reduced self-renewal at a young age. We propose that premature aging of HSCs, together with previously reported defects in class-switch recombination and memory immune response, underlies the progressive and severe lymphocytopenia in XLF-deficient patients in the absence of measurable V(D)J recombination defects.
Introduction
Nonhomologous end-joining (NHEJ) is a major DNA double-strand break (DSB) repair pathway. During lymphocyte development, NHEJ is required to rejoin programmed DSBs generated during V(D)J recombination. XRCC4-like factor (XLF, also called Cernunnos or NHEJ1) is 1 of 7 known NHEJ factors. Patients with germline homozygous inactivation mutations of XLF develop progressive lymphocytopenia, microcephaly, and occasional myeloproliferative disease.1,2 Although the role of XLF in NHEJ and V(D)J recombination was thought to explain the lymphocytopenia in XLF-deficient patients, we and others showed that XLF-deficient mice have no measurable defect in V(D)J recombination,3-6 highlighting the need for alternative mechanisms.
Hematopoietic stem cells (HSCs) differentiate to multipotent progenitors and then common lymphoid progenitors that eventually give rise to lymphocytes.7,8 DNA repair maintains the genomic stability throughout hematopoiesis and lymphocyte development beyond V(D)J recombination. Aged HSCs accumulate γ-H2AX foci, an indicator of DSB formation,9,10 lose self-renewal and reconstitution capacities, and preferentially commit to myeloid lineage at the price of lymphoid differentiation.11,12 Given the role of XLF in maintaining genomic stability in murine embryonic stem cells and human induced pluripotent stem cells,5,13 we investigated whether XLF preserves lymphogenesis by preventing premature aging of HSCs.
Study design
XLF-deficient mice were previously described.3 Recipient B6.SJL-PtprcaPep3b/BoyJ and competitor B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J mice were purchased from Jackson Laboratories. To sort HSCs, bone marrow (BM) cells were depleted of lineage+ cells using MACS columns (Miltenyi Biotec) after staining with anti-lineage biotin-conjugated antibodies (CD3ε, CD4, CD8α, B220, Mac1, Gr1, and Ter119) and then with fluorophore-conjugated streptavidin, anti-Sca-1, anti-c-Kit, anti-CD150, and anti-CD48 antibodies, and then sorted using FACSAriaII (Becton Dickinson). Flow cytometry data were collected using LSRII (BD) and analyzed with FlowJo. For transplantations, donor (CD45.2+) BM cells (1 × 106) or HSCs were injected into lethally irradiated (1200 cGy in 2 doses) recipient mice (CD45.1+), with 1 × 106 CD45.2+dsRed+ competitor BM cells. Peripheral blood (PB) mononuclear cells (MNCs) were analyzed for CD45.2, dsRed, and lineage markers (Thy-1.2, Mac1, Gr1, and B220) at 4, 10, and ≥17 weeks after transplantations. Ratio of donor to competitor percentages was used to determine reconstitutive capacity. Serial transplantations were performed at >20 weeks by injecting 1-2 × 106 BM cells from primary recipients of BM cells into lethally irradiated CD45.1+ secondary recipients. After 8 weeks, PB was analyzed as above, and serial reconstitution ability was measured by δ log ratio, which is the difference between the common logarithmic transformations of the average donor/competitor ratio in secondary recipients and the corresponding primary recipient.14 Alkaline comet assay was performed on purified lineagenegSca-1+c-Kit+ cells (Trevigen).
Results and discussion
Although lymphocyte count is only moderately reduced in 4-week-old XLF−/− mice,3 we found that peripheral B- and T-cell counts declined significantly faster in 4-, 12- and 24-month-old XLF−/− mice than in XLF+/+ littermates (Figure 1A-C). In BM, newly generated naïve B220lowIgM+ B-cells decreased earlier and faster in XLF−/− mice than in controls, leading to faster decline of total B220+ B cells in BM (Figure 1D-E). While in wild-type mice age-dependent reduction in de novo lymphogenesis is accompanied by accumulation of antigen-experienced B220highIgM+ B-cells, XLF−/− mice failed to accumulate B220highIgM+ B cells, further exacerbating the B-cell lymphocytopenia (Figure 1D). The frequency of BM red blood cell progenitors (Ter119+) and PB myeloid cells (Mac1+/Gr1+) did not decrease in aged XLF−/− mice (supplemental Figure 1B-C available at the Blood Web site), consistent with myeloid bias of aged HSCs and strict requirement for red blood cells for survival. These findings show that XLF-deficient mice recapitulate the severe progressive lymphocytopenia in XLF-deficient patients.
To determine whether HSC dysfunction contributes to the lymphocytopenia associated with XLF deficiency, we analyzed HSCs in XLF−/− mice using well-established markers (Figure 2A).15 Increased HSC number with declined function is a hallmark of HSC aging.16-18 Although the frequency and number of lineagenegSca-1+c-Kit+CD150+CD48− HSCs increased with age in both XLF−/− and XLF+/+ mice, XLF−/− mice harbored >2-fold more HSCs than controls at 6 and 12 months of age (Figure 2A-B). We then evaluated HSC function in competitive transplantations with BM cells from 3-, 6-, or 12-month-old XLF−/− mice or age-matched controls. Compared with controls, BM cells from 6- and 12-month-old, but not 3-month-old, XLF−/− mice had greatly reduced repopulation ability in MNCs, myeloid and B lineages (Figure 2C and supplemental Figure 2C). T-cell reconstitution was significantly lower in recipients of 12-month-old XLF−/− BM cells, likely due to the long half-life of T cells in PB (Figure 2C). Donor-derived myeloid vs B-cell ratio was consistently higher in recipients of XLF−/− BM cells than in recipients of control BM cells, indicating myeloid bias (Figure 2D). Together these data documented premature aging of XLF−/− HSCs, measured by their increased number, reduced trilineage reconstitution, and myeloid bias at a younger age.
Reconstitution in primary recipients of BM cells reflects a combined function of progenitor cells and HSCs. To determine the long-term repopulating capacity of HSCs specifically, we performed serial transplantations. Further reduction of reconstitution ability in secondary recipients relative to the corresponding primary recipient indicates a long-term repopulation defect in HSCs and is reflected as negative δ log ratio. Myeloid cells, the most short-lived cells in PB, are used as a readout of ongoing HSC function.19 Δ log ratio in myeloid cell reconstitution decreased significantly in the 6- and 12-month-old XLF−/− donor group, but not in age-matched controls (Figure 2E). Finally, in competitive transplantations with purified lineagenegSca-1+c-Kit+CD150+CD48− HSCs from ≥23-month-old XLF−/− mice and age-matched XLF+/− controls, XLF−/− HSCs had 27- and 41-fold lower reconstitution in myeloid and B-cell lineages, respectively (Figure 2F). Together, these data provide strong evidence for cell-intrinsic long-term repopulation defects in XLF−/− HSCs that worsen over time.
To determine whether XLF deficiency affects HSC self-renewal, we analyzed HSC chimerism in primary recipients in BM cells and HSC transplantations. The donor HSC chimerism decreased significantly in recipients of 12-month-old XLF−/− BM cells and aged HSCs, but not in those of 3- and 6-month-old XLF−/− BM cells, implying reduced self-renewal at advanced age (Figure 2G).
Ligase4 or Ku80, 2 other NHEJ factors, have been previously linked to HSC aging in murine models.9,20 However, Ku80 and Ligase4 are essential for V(D)J recombination, so the contribution of HSC dysfunction to lymphocytopenia cannot be evaluated in Ku80- or Ligase4-deficient mice. XLF is the only known NHEJ factor that is not strictly required for V(D)J recombination. XLF-deficient patients are diagnosed later in childhood or adolescence,1,21 compared with other NHEJ factor deficiencies, which are apparent in infancy. Given that most XLF mutations are truncation mutations,1,21 this delay cannot be simply explained by hypomorphism.
Here, we show that XLF-deficient mice display severe and progressive lymphocytopenia, reminiscent of the lymphocytopenia of XLF-deficient patients. XLF deficiency leads to accumulation of DNA damage in HSCs (supplemental Figure 3C) and premature aging of HSCs, evidenced by reduced trilineage reconstitution, self-renewal, and myeloid bias at young ages. In wild-type mice, memory lymphocytes accumulate throughout the lifetime to functionally compensate for the reduced de novo lymphogenesis at advanced age. However, the establishment and maintenance of memory immune response in XLF-deficient mice is compromised, likely due to defects in class switch recombination, a critical step in B-cell memory response, and in T-cell renewal.3,4,21 We conclude that premature aging of HSCs, combined with defective immune memory response, leads to severe progressive lymphocytopenia in XLF deficiency and potentially in other DNA-repair protein deficiency, such as WRN or ATM, independent of V(D)J recombination. In addition to age, the clinical presentation of XLF deficiency may also be influenced by genetic background, especially by the availability of redundant DNA-repair pathways.6,22,23
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
Acknowledgments
The authors thank Dr Richard Baer for his critical review of the manuscript.
This research was supported by National Institutes of Health grants 1R21AI103826 (S.Z., S.M.) from the National Institute of Allergy and Infectious Diseases, and 1RO1CA158073 (S.Z.) from the National Cancer Institute. S.Z. was a St Baldrick’s Scholar for Pediatric Cancer and is a Leukemia Lymphoma Society Scholar. J.L.C. is supported in part by National Institutes of Health grant TL1TR000082 from the National Cancer Institute.
Authorship
Contribution: S.Z. and S.M. conceived the study; S.A. and S.Z. designed and performed the experiments, analyzed the data, and wrote the manuscript; K.Y. performed the comet assay; M.C. and J.L.C. performed preliminary experiments; C.L. and B.J.L. maintained the XLF-deficient mouse colony; and T.Z. performed statistical analysis in Figure 1.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Shan Zha, Institute for Cancer Genetics, Columbia University Medical Center, 1130 St Nicholas Ave, Room 505, New York, NY 10032; e-mail: sz2296@columbia.edu.